SEC filings and other documents

All-stock merger forms a $421M company to accelerate innovative migraine therapies by 2026.

Q3 2026 net loss rose to $3.0M as R&D spending increased and commercial operations wind-down began.

Lead Alzheimer's candidate shows robust preclinical results; clinical trials targeted for 2027.

INM-901 advances to human trials as revenue drops 26% amid legislative risks.

INM-901 advanced toward clinical trials; revenue down 11% but cash supports milestones into 2026.

Promising preclinical results in Alzheimer's and dry AMD drive focus on partnerships and 2026 milestones.

INM-901 and INM-089 advanced, BayMedica sales rose 8%, and cash supports operations into Q4 2026.

Promising Alzheimer's and AMD drug candidates advance toward FDA meetings, with strong financial footing.

INM-901 shows strong preclinical promise for Alzheimer's, with commercial revenue supporting R&D.

INM-901 and INM-089 show promise as BayMedica sales rise but margins tighten.

Q4 2024 net loss widened to $2.58M; cash runway extends only through Q2 2025.

Revenue up 40% to $1.26M, but going concern risk persists without new funding.

Neuroinflammation is emerging as a critical target in Alzheimer's, with new therapies on the horizon.

INM grew BayMedica revenue 11%, advanced drug pipeline, and ended with $6.6M in cash.

Promising preclinical data in Alzheimer's and dry AMD, with strong financial and commercial support.